Eurofins Optimed
- Address
- 1 Rue Des Essarts
Sponsor Overview
Specializations
Healthy Volunteer and Early Human Safety
Eurofins Optimed supports clinical research centered on the initial evaluation of investigational medicines in healthy adult participants, with emphasis on safety, tolerability, pharmacokinetics, and pharmacodynamics. This area includes first-time exposure studies and controlled assessments of how new compounds behave in the body.
- First-in-human assessment
- Safety and tolerability monitoring
- Pharmacokinetic and pharmacodynamic profiling
The sponsor’s active portfolio reflects a strong interest in early translational research for novel therapeutic candidates entering human testing.
Neurology and Neurodevelopmental Disorders
Another key focus is the investigation of therapies relevant to Alzheimer’s disease and Down syndrome, indicating interest in conditions affecting cognition, brain function, and neurodevelopment. These studies address therapeutic questions linked to central nervous system activity and neurological impairment.
- Alzheimer’s disease
- Down syndrome
- Central nervous system therapeutics
This research area connects early-stage compound evaluation with disorders involving cognitive and neurological outcomes.
Toxicology and Antidote Development
Eurofins Optimed also funds clinical work in antitoxin and antidote research, with attention to agents intended to counter harmful biological exposures. The therapeutic interest in this domain lies in understanding how candidate treatments can support protection against or reversal of toxin-related effects.
- Antitoxin therapeutics
- Antidote research
- Exposure-related treatment development
This area highlights clinical interest in emergency-response and protective medical countermeasures.
Psychiatry and Epilepsy
The sponsor’s trial activity also extends to psychiatric disorders and epilepsy, reflecting engagement with conditions that involve brain excitability, behavior, and mental health. These therapeutic areas require careful clinical evaluation of candidate medicines affecting the central nervous system.
- Psychiatric disorders
- Epilepsy
- Neuropsychiatric treatment research
Research in these fields indicates interest in therapies for complex neurological and behavioral conditions.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of Leucettinib-21 Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects, Down Syndrome, and Alzheimer's Disease Patients |  France | Not Recruiting |
| Evaluation of Safety, Tolerability, and Pharmacokinetics of FBT-002 in Healthy Subjects | France | Not Recruiting |
| Phase I Evaluation of a Novel Compound in Healthy Volunteers for Potential Application in Psychiatric Disorders | France | Not Recruiting |
| Safety and Pharmacokinetic Evaluation of PTI5803 in Patients with Epilepsy | France | Not Recruiting |
Data & Insights
This sponsor works with 0 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 1 site across their trial portfolio.
Therapeutic Focus
- 1.Nervous System Diseases3 trials449 other sponsors
- 2.Not possible to specify1 trial220 other sponsors
Partnered Research Centres
1 centre- Address
- 1 Rue Des Essarts, 38610 Gieres
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Eurofins Optimed.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.